MAY 25, 2020 11:02 PM PDT

Potential Targets for Alcohol Induced Liver Disease

WRITTEN BY: Nouran Amin

Alcohol-related liver disease (ALD) is a fatal condition targeting more than 150 million people. Part of what makes it deadly is the unavailability of treatment besides a transplant. To address these challenges, researchers at Massachusetts General Hospital (MGH) have uncovered key molecular steps involved in ALD that may provide targets for drug therapy development.

Learn more about ALD:

The groundbreaking findings were published in Proceedings of the National Academy of Sciences (PNAS) and describes how researchers achieved their results by combining RNA sequence analysis of patient liver samples with transgenic mouse studies. Researchers were able to identify two promising potential molecular targets for developing ALD therapeutics-- cGAS and Cx32. The senior author is Suraj J. Patel, MD, PhD, a research fellow in the Department of Medicine.

"Now that we know the key players in this pathway, we finally have drug targets for treatment development," says the lead author on the study is Jay Luther, MD, gastroenterologist and Director of the Mass General Alcohol Liver Center. "Until now, we haven't had any successful leads. Meanwhile, the number of patients has grown."

Before the study, scientists already knew that liver cell (hepatocyte) death in ALD is supported IFN regulatory factor (IRF3) which fuels a strong secondary inflammatory response that affects nearby cells eventually leading to liver failure. However, the question they came up with was how does alcohol activate IRF3 and which pathways are amplified that deliver the disease spread throughout the liver.

"Until now, now we had only few clues about why alcohol-related liver disease progresses the way it does, but this research fills in key pieces of the puzzle," says Patel.

"It is very encouraging to see that we now have evidence-based targets for drug development for ALD," says Luther.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 03, 2021
Drug Discovery & Development
Keeping HIV Latent
MAR 03, 2021
Keeping HIV Latent
When (HIV) human immunodeficiency virus infects cells, it can go to sleep as opposed to make viral copies of itself&mdas ...
MAR 05, 2021
Drug Discovery & Development
Personalized Treatment for Sickle Cell Disease
MAR 05, 2021
Personalized Treatment for Sickle Cell Disease
Globally, the most prevalent inherited blood disease is sickle cell which affects 70,000 to 100,000 Americans. Despite s ...
APR 21, 2021
Drug Discovery & Development
Dietary Supplement Successfully Treats Mice with Schizophrenia
APR 21, 2021
Dietary Supplement Successfully Treats Mice with Schizophrenia
Researchers from the University of Tokyo have found that betaine, a dietary supplement found in sugar beets, reduces beh ...
MAY 12, 2021
Cardiology
Reversing the Heart Damage Seen in Marfan Syndrome
MAY 12, 2021
Reversing the Heart Damage Seen in Marfan Syndrome
Marfan syndrome is a genetic disorder that disrupts the connective tissues that anchor and link the body's organs, affec ...
MAY 17, 2021
Immunology
Understanding Inflammation: A Faster, Easier Way to Detect Cytokines in Cells
MAY 17, 2021
Understanding Inflammation: A Faster, Easier Way to Detect Cytokines in Cells
Inflammation, a process that was meant to defend our body from infection, has been found to contribute to a wide range o ...
MAY 15, 2021
Drug Discovery & Development
New Weight Loss Drug Converts Energy-Storing Fat into Energy-Burning Fat
MAY 15, 2021
New Weight Loss Drug Converts Energy-Storing Fat into Energy-Burning Fat
According to the World Health Organization (WHO), in 2016, around 2 billion adults around the world were overweight ...
Loading Comments...